Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D): Difference between revisions
(New page: {{Infobox_Disease | Name = Heart failure | Image = | Caption = | DiseasesDB = 16209 | ICD10 = {{ICD10|I|50|0|i|50}} | ICD9 = {{...) |
No edit summary |
||
Line 25: | Line 25: | ||
{{cquote| | {{cquote| | ||
===Class I=== | ===Class I=== | ||
1. Meticulous identification and control of fluid retention is recommended in patients with [[refractory endstage HF]]. ''(Level of Evidence: B)'' | |||
2. Referral for [[cardiac transplantation]] in potentially eligible patients is recommended for patients with [[refractory end-stage HF]]. ''(Level of Evidence: B)'' | |||
3. Referral of patients with [[refractory end-stage HF]] to an [[HF]] program with expertise in the management of [[refractory HF]] is useful. ''(Level of Evidence: A)'' | |||
4. Options for end-of-life care should be discussed with the patient and family when severe symptoms in patients with [[refractory end-stage HF]] persist despite application of all recommended therapies. ''(Level of Evidence: C)'' | |||
5. Patients with [[refractory end-stage HF]] and [[implantable defibrillators]] should receive information about the option to inactivate [[defibrillation]]. ''(Level of Evidence: C)'' | |||
===Class IIa=== | ===Class IIa=== |
Revision as of 17:10, 10 June 2009
Heart failure | |
ICD-10 | I50.0 |
---|---|
ICD-9 | 428.0 |
DiseasesDB | 16209 |
MedlinePlus | 000158 |
eMedicine | med/3552 |
MeSH | D006333 |
WikiDoc Resources for Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D) |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Cardiology Network |
Discuss Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D) further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Template:WikiDoc Cardiology News Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview of Treatment of Patients with Refractory End-Stage Heart Failure (Stage D)
ACC / AHA Guidelines- Treatment of Patients with Refractory End-Stage Heart Failure (Stage D) (DO NOT EDIT) [1]
“ |
Class I1. Meticulous identification and control of fluid retention is recommended in patients with refractory endstage HF. (Level of Evidence: B) 2. Referral for cardiac transplantation in potentially eligible patients is recommended for patients with refractory end-stage HF. (Level of Evidence: B) 3. Referral of patients with refractory end-stage HF to an HF program with expertise in the management of refractory HF is useful. (Level of Evidence: A) 4. Options for end-of-life care should be discussed with the patient and family when severe symptoms in patients with refractory end-stage HF persist despite application of all recommended therapies. (Level of Evidence: C) 5. Patients with refractory end-stage HF and implantable defibrillators should receive information about the option to inactivate defibrillation. (Level of Evidence: C) Class IIaClass IIbClass III |
” |
See Also
Sources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202